An update on chemotherapy of colorectal liver metastases

World Journal of Gastroenterology

Volumn 18, Issue 1, 2012, Pages 25-33

  Wang, Chen Chen ^a,b   Li, Jin ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

Chemotherapy; Colorectal cancer; Liver metastases; Resection rate; Targeted agents

Indexed keywords

CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COLORECTAL CANCER; DISEASE FREE SURVIVAL; HUMAN; INOPERABLE CANCER; LIVER METASTASIS; LIVER RESECTION; OVERALL SURVIVAL; PERIOPERATIVE PERIOD; PREOPERATIVE CARE; SURVIVAL TIME; TREATMENT RESPONSE;

EID: 84862954399     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v18.i1.25     Document Type: Article

References (69)

1. Ruers T, Bleichrodt RP. Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002; 38: 1023-1033
2. Stangl R, Altendorf-Hofmann A, Charnley RM, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994; 343: 1405-1410
3. Fong Y, Cohen AM, Fortner JG, Enker WE, Turnbull AD, Coit DG, Marrero AM, Prasad M, Blumgart LH, Brennan MF. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938-946
4. Mentha G, Majno P, Terraz S, Rubbia-Brandt L, Gervaz P, Andres A, Allal AS, Morel P, Roth AD. Treatment strategies for the management of advanced colorectal liver metastases detected synchronously with the primary tumour. Eur J Surg Oncol 2007; 33 Suppl 2: S76-S83
5. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Korn-prat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 2007; 25: 4575-4580
6. Nordlinger B, Van Cutsem E, Rougier P, Köhne CH, Ychou M, Sobrero A, Adam R, Arvidsson D, Carrato A, Georgou-lias V, Giuliante F, Glimelius B, Golling M, Gruenberger T, Tabernero J, Wasan H, Poston G. Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group. Eur J Cancer 2007; 43: 2037-2045
7. Van Cutsem E, Nordlinger B, Adam R, Köhne CH, Pozzo C, Poston G, Ychou M, Rougier P. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer 2006; 42: 2212-2221
8. Nordlinger B, Van Cutsem E, Gruenberger T, Glimelius B, Poston G, Rougier P, Sobrero A, Ychou M. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol 2009; 20: 985-992
9. Robinson S, Manas DM, Pedley I, Mann D, White SA. Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surg Oncol 2011; 20: 57-72
10. Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, Belghiti J, Piedbois P, Guimbaud R, Nordlinger B, Bugat R, Lazorthes F, Bedenne L. Multicenter randomized trial of adjuvant fuorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24: 4976-4982
11. Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, Nitti D, Torri V, Elias D, O'Callaghan C, Langer B, Marti-gnoni G, Bouché O, Lazorthes F, Van Cutsem E, Bedenne L, Moore MJ, Rougier P. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008; 26: 4906-4911
12. Parks R, Gonen M, Kemeny N, Jarnagin W, D'Angelica M, DeMatteo R, Garden OJ, Blumgart LH, Fong Y. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: analysis of data from two continents. J Am Coll Surg 2007; 204: 753-761; discussion 761-763
13. Kornprat P, Jarnagin WR, Gonen M, DeMatteo RP, Fong Y, Blumgart LH, D'Angelica M. Outcome after hepatec-tomy for multiple (four or more) colorectal metastases in the era of effective chemotherapy. Ann Surg Oncol 2007; 14: 1151-1160
14. Ychou M, Hohenberger W, Thezenas S, Navarro M, Maurel J, Bokemeyer C, Shacham-Shmueli E, Rivera F, Kwok-Keung Choi C, Santoro A. A randomized phase III study comparing adjuvant 5-fuorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann Oncol 2009; 20: 1964-1970
15. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 2007; 16: 71-83
16. Karanjia ND, Lordan JT, Fawcett WJ, Quiney N, Worthing-ton TR. Survival and recurrence after neo-adjuvant chemotherapy and liver resection for colorectal metastases: a ten year study. Eur J Surg Oncol 2009; 35: 838-843
17. Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
18. Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008; 8: 120
19. Gruenberger B, Tamandl D, Schueller J, Scheithauer W, Zie-linski C, Herbst F, Gruenberger T. Bevacizumab, capecitabi-ne, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J Clin Oncol 2008; 26: 1830-1835
20. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680
21. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sin-nige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572
22. Adam R. Chemotherapy and surgery: new perspectives on the treatment of unresectable liver metastases. Ann Oncol 2003; 14 Suppl 2: 13-16
23. Khatri VP, Chee KG, Petrelli NJ. Modern multimodality approach to hepatic colorectal metastases: solutions and controversies. Surg Oncol 2007; 16: 71-83
24. Alberts SR, Horvath WL, Sternfeld WC, Goldberg RM, Ma-honey MR, Dakhil SR, Levitt R, Rowland K, Nair S, Sargent DJ, Donohue JH. Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23: 9243-9249
25. Pozzo C, Basso M, Cassano A, Quirino M, Schinzari G, Trigila N, Vellone M, Giuliante F, Nuzzo G, Barone C. Neo-adjuvant treatment of unresectable liver disease with irino-tecan and 5-fuorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15: 933-939
26. Barone C, Nuzzo G, Cassano A, Basso M, Schinzari G, Giu-liante F, D'Argento E, Trigila N, Astone A, Pozzo C. Final analysis of colorectal cancer patients treated with irinotecan and 5-fluorouracil plus folinic acid neoadjuvant chemotherapy for unresectable liver metastases. Br J Cancer 2007; 97: 1035-1039
27. Hind D, Tappenden P, Tumur I, Eggington S, Sutcliffe P, Ryan A. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2008; 12: 3-9, 9-162
28. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, Cortesi E, Picone V, Vitello S, Chiara S, Granetto C, Porcile G, Fioretto L, Orlandini C, Andreuccetti M, Masi G. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fuorouracil, leucovorin, and irinotecan (FOLFIRI) as frst-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
29. Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Ricci S, Brunetti IM, Ferraldeschi R, Naso G, Filipponi F, Pietrabissa A, Goletti O, Baldi G, Fornaro L, Andreuccetti M, Falcone A. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leu-covorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg 2009; 249: 420-425
30. Ychou M, Viret F, Kramar A, Desseigne F, Mitry E, Gui-mbaud R, Delpero JR, Rivoire M, Quénet F, Portier G, Nordlinger B. Tritherapy with fuorouracil/leucovorin, iri-notecan and oxaliplatin (FOLFIRINOX): a phase II study in colorectal cancer patients with non-resectable liver metasta-ses. Cancer Chemother Pharmacol 2008; 62: 195-201
31. Rivoire M, Thezenas S, Rebischung C, Viret F, Guimbaud R, Francois E, Ducreux M, Quenet F, Desseigne F, Ychou M. Preliminary results of a randomized phase II trial comparing standard bi-therapy versus three intensifed chemotherapy regimens as treatment for patients with non resectable liver metastases from colorectal cancer (METHEP). J Clin Oncol 2008; 26: a4075
32. Adam R, Pascal G, Castaing D, Azoulay D, Delvart V, Paule B, Levi F, Bismuth H. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 2004; 240: 1052-1061; discussion 1061-1064
33. Seymour MT, Maughan TS, Ledermann JA, Topham C, James R, Gwyther SJ, Smith DB, Shepherd S, Maraveyas A, Ferry DR, Meade AM, Thompson L, Griffths GO, Parmar MK, Stephens RJ. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152
34. Brouquet A, Overman MJ, Kopetz S, Maru DM, Loyer EM, Andreou A, Cooper A, Curley SA, Garrett CR, Abdalla EK, Vauthey JN. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justifed? Cancer 2011; 117: 4484-4492
35. de Haas RJ, Wicherts DA, Flores E, Azoulay D, Castaing D, Adam R. R1 resection by necessity for colorectal liver metas-tases: is it still a contraindication to surgery? Ann Surg 2008; 248: 626-637
36. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417
37. Bokemeyer C, Bondarenko I, Hartmann JT, De Braud FG, Volovat C, Nippgen J, Stroh C, Celik I, Koralewski P. KRAS status and efficacy of first-line treatment of patientswith-metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008; 26: a4000
38. Van Cutsem E, Lang I, D'haens G, Moiseyenko V, Zaluski J, Folprecht G, Tejpar S, Kisker O, Stroh C, Rougier P. KRAS status and effcacy in the frst-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol 2008; 26: a2
39. Kohne C, Stroiakovski D, Chang-chien C, Lim R, Pintér T, Bodoky G, Stroh C, Celik I, Rougier P, VanCutsem E. Predictive biomarkers to improve treatment of metastatic colorectal cancer (mCRC): Outcomes with cetuximab plus FOLFIRI in the CRYSTAL trial. J Clin Oncol 2009; 27: a4068
40. Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, Lang H, Frilling A, Stoehlmacher J, Weitz J, Konopke R, Stroszczynski C, Liersch T, Ockert D, Herrmann T, Goekkurt E, Parisi F, Köhne CH. Tumour response and secondary resectability of colorectal liver metas-tases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol 2010; 11: 38-47
41. Adam R, Aloia T, Lévi F, Wicherts DA, de Haas RJ, Paule B, Bralet MP, Bouchahda M, Machover D, Ducreux M, Castagne V, Azoulay D, Castaing D. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy. J Clin Oncol 2007; 25: 4593-4602
42. Central European Cooperative Oncology Group, Ciuleanu TE, Scheithauer W, Kurteva G, Ocvirk J, Koza I, Papami-chael D, Wenczl M, Brodowicz T, Beslija S, Zielinski CC. A randomized open-label phase II study evaluating the efficacy and safety of FOLFOX6 cetuximab versus FOLFIRI cetuximab as frst-line therapy in patients (pts) with meta-static colorectal cancer (MCRC). ASCO Gastrointest Cancers Symp 2008: a339
43. Venook AP, Niedzwiecki D, Hollis D, Sutherland S, Goldberg R, Alberts S, Benson A, Wade J, Schilsky R, Mayer R. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) 6 cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results. J Clin Oncol 2006; 24: 3509
44. Heinemann V, Moosman N, Vehling-Kaiser U, Stauch M, Oruzio D, Schulze M, Walther J, Weiss J, Dietzfelbinger H, Fischer Von Weikersthal L. XELIRI plus cetuximab versus XELOX plus cetuximab for the first-line therapy of meta-static colorectal cancer (CRC): a randomized trial of the AIO CRC study group. ASCO Gastrointest Cancers Symp 2007: a278
45. Maughan TS, Adams RA, Smith CG, Meade AM, Seymour MT, Wilson RH, Idziaszczyk S, Harris R, Fisher D, Kenny SL, Kay E, Mitchell JK, Madi A, Jasani B, James MD, Bridge-water J, Kennedy MJ, Claes B, Lambrechts D, Kaplan R, Cheadle JP. Addition of cetuximab to oxaliplatin-based frst-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114
46. Maughan T, Adams RA, Smith CG, Seymour MT, Wilson RH, Meade AM, Fisher D, Madi A, Cheadle J, Kaplan RS. Identification of potentially responsive subsets when ce-tuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in frst-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial. J Clin Oncol 2010; 28: a3502
47. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with frst-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038
48. Garuf C, Torsello A, Tumulo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Pizzi G, Ettorre GM, Sperduti I. POCHER (preoperative chemotherapy for hepatic resection) study with cetuximab (Cmab) plus CPT-11/5-fuorouracil (5-FU)/ leucovorin (FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unre-sectable colorectal liver metastases(CLM). J Clin Oncol 2009; 27: ae15020
49. Ychou M, Desseigne F, Thezenas S, Viret F, Mineur L, As-senat E, Bleuse J, Kramar A, Portales F, Samalin E. Preliminary results of a of a mutli-center phase II trial evaluating cetuximab in combination with FOLFIRINOX (LV5FU irinotecan oxaliplatin) as first-line treatment of metastatic colorectal cancer (mCRC). ASCO Gastrointest Cancers Symp 2009: a450
50. Bokemeyer C, Kohne C, Rougier P, Stroh C, Schlichting M, Van Cutsem E. Cetuximab with chemotherapy (CT) as frst-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status. J Clin Oncol 2010; 28: a3506
51. Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with frst-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009; 101: 1033-1038
52. Saltz LB, Clarke S, Díaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang TS, Rivera F, Couture F, Sirzén F, Cassidy J. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
53. Falcone A, Masi G, Loupakis F, Vasile E, Ciarlo A, Cava-ciocchi D, Amoroso D, Puglisi M, Fea E, Brunetti I. FOLF-OXIRI (irinotecan, oxaliplatin, and infusional 5FU/LV) in combination with bevacizumab in the frst-line treatment of metastatic colorectal cancer: a phase II study by the G.O.N.O. group. J Clin Oncol 2008; 26: a4031
54. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Gro-chow L, Jaffe C, Rubinstein L, Zwiebel J, Kaplan RS. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: an NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006; 24: 3354-3360
55. Wolmark N, Yothers G, O'Connell MJ, Sharif S, Atkins JN, Seay TE, Feherenbacher L, O'Reilly S, Allegra CJ. A phase III trial comparing mFOLFOX6 to mFOLFOX6 plus beva-cizumab in stage II or III carcinoma of colon: Results of NSABP Protocol C-08. J Clin Oncol 2009; 27: LBA4
56. Macarulla T, Capdevila J, Perez-Garcia J, Ramos FJ, Elez ME, Markman B, Ruiz-Echarri M, Tabernero J. New approaches and targets in advanced colorectal cancer. Eur J Cancer 2009; 45 Suppl 1: 79-88
57. Wagman LD, Byun TE. Managing colorectal cancer liver metastases. Oncology (Williston Park) 2009; 23: 1063-1071
58. Miyanari N, Mori T, Takahashi K, Yasuno M. Evaluation of aggressively treated patients with unresectable multiple liver metastases from colorectal cancer. Dis Colon Rectum 2002; 45: 1503-1509
59. van Riel JM, van Groeningen CJ, Albers SH, Cazemier M, Meijer S, Bleichrodt R, van den Berg FG, Pinedo HM, Gi-accone G. Hepatic arterial 5-fluorouracil in patients with liver metastases of colorectal cancer: single-centre experience in 145 patients. Ann Oncol 2000; 11: 1563-1570
60. Link KH, Pillasch J, Formentini A, Sunelaitis E, Leder G, Saf F, Kornmann M, Beger HG. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver me-tastases. Eur J Surg Oncol 1999; 25: 381-388
61. Mocellin S, Pasquali S, Nitti D. Fluoropyrimidine-HAI (hepatic arterial infusion) versus systemic chemotherapy (SCT) for unresectable liver metastases from colorectal cancer. Co-chrane Database Syst Rev 2009; CD007823
62. Kemeny NE, Niedzwiecki D, Hollis DR, Lenz HJ, Warren RS, Naughton MJ, Weeks JC, Sigurdson ER, Herndon JE, Zhang C, Mayer RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of effcacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 2006; 24: 1395-1403
63. Ducreux M, Ychou M, Laplanche A, Gamelin E, Lasser P, Husseini F, Quenet F, Viret F, Jacob JH, Boige V, Elias D, Delperro JR, Luboinski M. Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2005; 23: 4881-4887
64. Boige V, Malka D, Elias D, Castaing M, De Baere T, Goere D, Dromain C, Pocard M, Ducreux M. Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 2008; 15: 219-226
65. Nelson R, Freels S. Hepatic artery adjuvant chemotherapy for patients having resection or ablation of colorectal cancer metastatic to the liver. Cochrane Database Syst Rev 2006; CD003770
66. Kemeny N, Huang Y, Cohen AM, Shi W, Conti JA, Bren-nan MF, Bertino JR, Turnbull AD, Sullivan D, Stockman J, Blumgart LH, Fong Y. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341: 2039-2048
67. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352: 734-735
68. Rudroff C, Altendorf-Hoffmann A, Stangl R, Scheele J. Prospective randomised trial on adjuvant hepatic-artery infusion chemotherapy after R0 resection of colorectal liver metastases. Langenbecks Arch Surg 1999; 384: 243-249
69. Kemeny MM, Adak S, Gray B, Macdonald JS, Smith T, Lip-sitz S, Sigurdson ER, O'Dwyer PJ, Benson AB. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 2002; 20: 1499-1505